The PI3K/Akt pathway tends to upregulate in 30–50% of prostate cancers, and molecular changes have been demonstrated in the PI3K/Akt to distinguish malignant from benign prostatic epithelium and have been related with growing tumor grade, stage, and risk of recurrence (Luo et al., 2003; Hennessy et al., 2005; Morgan et al., 2009). Here, AKT1 is linked to prostate cancer.